| Primary |
| Sepsis |
12.3% |
| Pyrexia |
11.5% |
| Hypertension |
9.0% |
| Delirium |
4.9% |
| Hypercalcaemia |
4.9% |
| Mediastinal Abscess |
4.9% |
| Neutropenic Infection |
4.9% |
| Thrombosis Prophylaxis |
4.9% |
| Urinary Tract Infection |
4.9% |
| Ear Infection |
4.1% |
| Pain |
4.1% |
| Tremor |
4.1% |
| Depression |
3.3% |
| Hallucination |
3.3% |
| Pneumonia |
3.3% |
| Pneumonia Bacterial |
3.3% |
| Prophylactic Chemotherapy |
3.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.3% |
| Toxoplasmosis |
3.3% |
| Abscess |
2.5% |
|
| Toxic Epidermal Necrolysis |
18.2% |
| Sepsis |
9.1% |
| Acute Generalised Exanthematous Pustulosis |
6.1% |
| Anaphylactic Reaction |
6.1% |
| Respiratory Arrest |
6.1% |
| Skin Hyperpigmentation |
6.1% |
| Thrombocytopenia |
6.1% |
| Tubulointerstitial Nephritis |
6.1% |
| Chills |
3.0% |
| Cholecystitis |
3.0% |
| Drug Interaction |
3.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.0% |
| Gastroenteritis Clostridial |
3.0% |
| Haemolysis |
3.0% |
| Haemorrhagic Anaemia |
3.0% |
| Hypernatraemia |
3.0% |
| Hypokalaemia |
3.0% |
| Incorrect Dose Administered |
3.0% |
| International Normalised Ratio Increased |
3.0% |
| Jaundice Cholestatic |
3.0% |
|
| Secondary |
| Product Used For Unknown Indication |
18.4% |
| Electrolyte Substitution Therapy |
12.7% |
| Hypertension |
8.8% |
| Stupor |
6.1% |
| Arthritis |
5.3% |
| Sepsis |
5.3% |
| Pain |
5.1% |
| Supplementation Therapy |
4.9% |
| Thrombosis Prophylaxis |
4.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.9% |
| Pneumonia |
3.3% |
| Restlessness |
3.1% |
| Pyrexia |
2.9% |
| Heart Transplant |
2.5% |
| Bacterial Infection |
2.3% |
| Constipation |
2.3% |
| Hyperglycaemia |
2.3% |
| Depression |
2.0% |
| Hypotension |
2.0% |
| Hypothyroidism |
2.0% |
|
| Toxic Epidermal Necrolysis |
29.8% |
| Monocytopenia |
8.8% |
| Sepsis |
7.0% |
| Pancreatic Enzymes Increased |
5.3% |
| Stevens-johnson Syndrome |
5.3% |
| Drug Interaction |
3.5% |
| Leukopenia |
3.5% |
| Prothrombin Time Prolonged |
3.5% |
| Rash |
3.5% |
| Renal Failure Acute |
3.5% |
| Respiratory Arrest |
3.5% |
| Skin Hyperpigmentation |
3.5% |
| Surgery |
3.5% |
| Thrombocytopenia |
3.5% |
| Urosepsis |
3.5% |
| Blood Lactate Dehydrogenase Increased |
1.8% |
| Chills |
1.8% |
| Cholecystitis |
1.8% |
| Epilepsy |
1.8% |
| Haemolysis |
1.8% |
|
| Concomitant |
| Prophylaxis |
15.1% |
| Product Used For Unknown Indication |
10.9% |
| Infection |
10.4% |
| Hypertension |
7.0% |
| Constipation |
6.1% |
| Sepsis |
6.0% |
| Drug Use For Unknown Indication |
5.3% |
| Pneumonia |
4.8% |
| Nausea |
4.1% |
| Acute Myeloid Leukaemia |
3.8% |
| Bacterial Infection |
3.7% |
| Pyrexia |
3.1% |
| Fungal Infection |
3.0% |
| Sedation |
3.0% |
| Lung Infection |
2.8% |
| Infection Prophylaxis |
2.7% |
| Pain |
2.3% |
| Prophylaxis Against Transplant Rejection |
2.2% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Colorectal Cancer Metastatic |
2.0% |
|
| Thrombocytopenia |
13.4% |
| Sepsis |
10.3% |
| Ureterostomy Site Discomfort |
10.3% |
| Vomiting |
8.2% |
| Urinary Retention |
7.2% |
| Renal Failure |
6.2% |
| Jaundice |
5.2% |
| Multi-organ Failure |
5.2% |
| Pyrexia |
4.1% |
| Tumour Haemorrhage |
4.1% |
| Renal Failure Acute |
3.1% |
| Septic Shock |
3.1% |
| Transaminases Increased |
3.1% |
| Urinary Tract Infection |
3.1% |
| Vertigo |
3.1% |
| Acute Myocardial Infarction |
2.1% |
| Gastric Bypass |
2.1% |
| Haematochezia |
2.1% |
| Hypotension |
2.1% |
| Left Ventricular Dysfunction |
2.1% |
|
| Interacting |
| Atrial Fibrillation |
21.9% |
| Pneumonia |
12.5% |
| Renal Failure Chronic |
12.5% |
| Antibiotic Prophylaxis |
6.3% |
| Cardiac Failure Congestive |
6.3% |
| Gastritis |
6.3% |
| Pyrexia |
6.3% |
| Thyroid Disorder |
6.3% |
| Atrial Flutter |
3.1% |
| Constipation |
3.1% |
| Epilepsy |
3.1% |
| Essential Hypertension |
3.1% |
| Influenza |
3.1% |
| Pneumonia Bacterial |
3.1% |
| Sleep Disorder |
3.1% |
|
| Drug Interaction |
75.0% |
| Hypokalaemia |
25.0% |
|
